(0.11%) 5 475.09 points
(0.11%) 39 155 points
(0.43%) 17 793 points
(-0.20%) $80.67
(-3.66%) $2.66
(-0.77%) $2 312.90
(0.18%) $28.92
(3.45%) $1 020.40
(0.27%) $0.936
(0.68%) $10.68
(0.45%) $0.792
(-0.27%) $87.25
Live Chart Being Loaded With Signals
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers...
Stats | |
---|---|
今日成交量 | 85 |
平均成交量 | 4 572 |
市值 | 23.08M |
EPS | $-0.130 ( Q4 | 2023-12-31 ) |
下一个收益日期 | ( $0 ) 2024-07-22 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-6.90 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0 (0.00%) |
CytoMed Therapeutics 相关性
10 最正相关 |
---|
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
CytoMed Therapeutics 财务报表
Annual | 2023 |
营收: | $507 735 |
毛利润: | $504 007 (99.27 %) |
EPS: | $-0.390 |
FY | 2023 |
营收: | $507 735 |
毛利润: | $504 007 (99.27 %) |
EPS: | $-0.390 |
FY | 2022 |
营收: | $363 912 |
毛利润: | $355 192 (97.60 %) |
EPS: | $-0.410 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
CytoMed Therapeutics
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers. The company\'s lead product candidate is CTM-N2D, which consists of expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, which utilizes iPSC as a starting material to generate gdNKT, a synthetic hybrid of a gamma delta T cell and a NK cell; and CTM-GDT, a product candidate that consists of expanded gamma delta T cells, and exploits the multiple recognition system of gamma delta T cell to recognize and treat a range of cancers. The company was incorporated in 2018 and is headquartered in Singapore.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。